A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2017
Price : $35 *
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Docetaxel; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Roche
- 18 Jan 2017 Status changed from completed to discontinued.
- 04 Nov 2016 Status changed from active, no longer recruiting to completed.
- 29 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.